CF drug maker offers treatment at surcharge of €23,000 per patient
Cystic Fibrosis Ireland boss says ‘no justification for price differential’ with Britain
The manufacturer of the breakthrough Cystic Fibrosis drug called Orkambi proposed charging €23,000 more per person for its drug in Ireland compared with England.
Vertex offered a €158,000 price tag per patient per year to the Irish health service in the submission it made a few months ago.
Vertex then offered England’s National Health Service (NHS) a list price of €135,000 (£104,000) per patient per year.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
*New subscribers only
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team
Beacon Hospital signs Covid-19 surge capacity deal with HSE
The only private hospital in the state to have rejected deal has now agreed to provide beds to public health system during crisis
We’re paying the price for ignored advice on lifting of lockdowns
The government’s mistake is that it continues to regard public health and economic wellbeing as competing interests, forever diametrically opposed to each other, instead of recognising that one can’t thrive without the other